Oak Thistle LLC Buys 9,197 Shares of Henry Schein, Inc. $HSIC

Oak Thistle LLC boosted its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 157.1% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 15,052 shares of the company’s stock after purchasing an additional 9,197 shares during the period. Oak Thistle LLC’s holdings in Henry Schein were worth $1,257,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of HSIC. CYBER HORNET ETFs LLC purchased a new stake in Henry Schein in the second quarter worth about $25,000. MUFG Securities EMEA plc purchased a new position in shares of Henry Schein during the 2nd quarter valued at about $27,000. Flagship Harbor Advisors LLC purchased a new position in shares of Henry Schein during the 4th quarter valued at about $30,000. Federated Hermes Inc. bought a new position in shares of Henry Schein during the 4th quarter valued at approximately $32,000. Finally, Los Angeles Capital Management LLC bought a new position in shares of Henry Schein during the 4th quarter valued at approximately $37,000. Institutional investors own 96.62% of the company’s stock.

Henry Schein Stock Performance

NASDAQ:HSIC opened at $90.74 on Thursday. The stock has a 50-day moving average price of $84.28 and a 200 day moving average price of $78.89. The stock has a market capitalization of $10.11 billion, a P/E ratio of 26.45, a P/E/G ratio of 1.70 and a beta of 0.80. Henry Schein, Inc. has a 12-month low of $61.94 and a 12-month high of $92.18. The company has a current ratio of 1.32, a quick ratio of 0.73 and a debt-to-equity ratio of 0.60.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $1.27 EPS for the quarter, topping analysts’ consensus estimates of $1.24 by $0.03. Henry Schein had a return on equity of 15.97% and a net margin of 2.96%.The company had revenue of $3.46 billion for the quarter, compared to analysts’ expectations of $3.37 billion. During the same period in the previous year, the firm earned $1.10 EPS. The firm’s revenue was up 6.7% compared to the same quarter last year. Henry Schein has set its FY 2026 guidance at 5.290-5.390 EPS. Equities research analysts forecast that Henry Schein, Inc. will post 5.35 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on HSIC shares. Weiss Ratings restated a “hold (c+)” rating on shares of Henry Schein in a research note on Friday, July 31st. Morgan Stanley reiterated an “underweight” rating and issued a $64.00 price target (up from $61.00) on shares of Henry Schein in a research report on Friday, April 24th. Stifel Nicolaus set a $95.00 price objective on shares of Henry Schein in a research note on Wednesday, August 5th. Barclays restated an “overweight” rating and set a $100.00 price objective (up from $86.00) on shares of Henry Schein in a research report on Thursday, August 6th. Finally, Barrington Research set a $104.00 target price on shares of Henry Schein in a research note on Wednesday, August 5th. Eight equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $92.27.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.